1076199-23-9

Basic information

• Product Name: N-Boc-N-Desmethyl Imatinib
• Synonyms: N-Boc-N-Desmethyl Imatinib;4-[[4-[[[4-Methyl-3-[[4-(3-pyridinyl)-2-pyriMidinyl]aMino]phenyl]aMino]carbonyl]phenyl]Methyl]-1-piperazinecarboxylic Acid 1,1-DiMethylethyl Ester;IMatinib IMpurity A
• CAS NO: 1076199-23-9
• Molecular Formula: C33H37N7O3
• Molecular Weight: 579.69198
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors
• Mol File: 1076199-23-9.mol

Chemical Properties

• Melting Point: 115-120°C
• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Methanol
• CAS DataBase Reference: N-Boc-N-Desmethyl Imatinib(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-N-Desmethyl Imatinib(1076199-23-9)
• EPA Substance Registry System: N-Boc-N-Desmethyl Imatinib(1076199-23-9)

Safety Data

• Hazardous Substances Data: 1076199-23-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

Imatinib derivative

Upstream product

• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 404844-11-7 4-(chloromethyl)-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]-amino}phenyl)benzamide 
• 479353-63-4 (4-(4-(tert-butoxycarbonyl)piperazin-1-yl)methyl)benzoic acid 
• 152460-10-1 6-methyl-1-N-(4-(pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 
• 619-66-9 4-Carboxybenzaldehyde 
• 120465-56-7 4-(dimethoxymethyl)benzoic acid 

Relevant articles and documents

Haptens, antigens and antibodies of imatinib and N-demethylated imatinib and application thereof

The invention relates to the technical field of immunological detection, and particularly discloses haptens, antigens and antibodies of imatinib and N-demethylated imatinib and application of the haptens, the antigens and the antibodies, the structure of

Development of Gleevec Analogues for Reducing Production of β-Amyloid Peptides through Shifting β-Cleavage of Amyloid Precursor Proteins

Imatinib mesylate, 1a, inhibits production of β-amyloid (Aβ) peptides both in cells and in animal models. It reduces both the β-secretase and γ-secretase cleavages of the amyloid precursor protein (APP) and mediates a synergistic effect, when combined with a β-secretase inhibitor, BACE IV. Toward developing more potent brain-permeable leads, we have synthesized and evaluated over 75 1a-analogues. Several compounds, including 2a-b and 3a-c, inhibited production of Aβ peptides with improved activity in cells. These compounds affected β-secretase cleavage of APP similarly to 1a. Compound 2a significantly reduced production of the Aβ42 peptide, when administered (100 mg/kg, twice daily by oral gavage) to 5 months old female mice for 5 days. A combination of compound 2a with BACE IV also reduced Aβ levels in cells, more than the additive effect of the two compounds. These results open a new avenue for developing treatments for Alzheimer's disease using 1a-analogues.

FATTY ACID ANTICANCER DERIVATIVES AND THEIR USES

The invention relates to fatty acid anticancer derivatives; compositions comprising an effective amount of a fatty acid anticancer derivative; and methods for treating or preventing cancer comprising the administration of an effective amount of a fatty ac